Optigo Biotherapeutics Develops Long-Acting Anti-VEGF Therapy with Six-Month Dosing Potential
核心洞察
Optigo Biotherapeutics (搜索) won the People's Choice Award at Eyecelerator 2025 for its proprietary drug anchoring technology that could transform intravitreal drug delivery.
The company's preclinical data demonstrates sustained efficacy and safety for six months or more following a single injection of their bi-functional anti-VEGF (搜索) molecules.
The fusion proteins combine aflibercept with albumin or hyaluronan anchoring domains, showing 2-3x longer half-life compared to aflibercept alone in animal models.
Optigo Biotherapeutics (搜索) has achieved a significant milestone in ophthalmology drug development, winning the People's Choice Award at Eyecelerator 2025 in Park City, Utah, while presenting compelling preclinical data on long-acting intravitreal biologics at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting. The biotechnology company's proprietary anti-VEGF (搜索) molecules demonstrate the potential to achieve dosing intervals of six months or longer in patients with neovascular age-related macular degeneration (搜索) (nAMD), diabetic macular edema (搜索) (DME), and retinal vein occlusion (搜索) (RVO).
Revolutionary Drug Anchoring Technology
The company's breakthrough lies in its bi-functional intravitreal biologics, which are fusion proteins that combine established therapeutics such as aflibercept with an albumin or hyaluronan anchoring domain. This innovative approach addresses a critical limitation in current anti-VEGF (搜索) therapies by dramatically reducing dosing frequency.
"Our bi-functional intravitreal biologics are designed to fundamentally address the limitations of current anti-VEGF (搜索) therapies by dramatically reducing the dosing frequency," said Houman Hemmati, MD, PhD, Chief Medical Officer and Co-founder of Optigo Bio. "The recognition from industry peers at Eyecelerator, along with the compelling preclinical data we shared at ARVO, underscore both the innovation and real-world potential of our platform."
Promising Preclinical Results
In VEGF (搜索) challenge animal models, Optigo's bifunctional molecules demonstrated remarkable performance characteristics. The molecules showed 2-3x longer half-life compared to aflibercept alone, were not proinflammatory, and were well tolerated with a favorable safety profile. The preclinical data demonstrates sustained efficacy and safety for six months or more following a single injection.
Dr. David Boyer, retina specialist at Retina Vitreous Associates Medical Group (搜索), provided expert commentary on the significance of these findings: "I'm particularly excited about the data Optigo Bio presented at ARVO. The favorable preclinical safety profile combined with their anchoring technology, which enhances half-life and efficacy, represents a promising new treatment option for patients with nAMD and other retinal neovascular diseases."
Addressing Market Needs
The technology addresses a significant clinical challenge in retinal disease management. Ali Ardakani, CEO and Co-founder of Optigo Bio, explained the real-world impact: "While anti-VEGF (搜索) therapies have significantly reduced blindness globally, real-world outcomes are limited by the burdensome injection schedule. Our platform addresses this bottleneck directly by offering biologics that deliver real efficacy with fewer injections."
Optigo's presentation at Eyecelerator, titled "Developing Breakthrough Therapies to Restore Vision," was delivered by Dr. Hemmati during the Retina TKI and Drug Delivery Showcase. The presentation was well-received by attendees for its evidence-backed approach to solving one of the biggest challenges of chronic intravitreal therapy.
Market Positioning and Future Outlook
The company's technology is strategically positioned to capture a significant portion of the growing $14 billion anti-VEGF (搜索) market by improving patient adherence and outcomes. Optigo's modular platform has broad applicability across retinal biologics requiring extended duration, suggesting potential applications beyond the current focus areas.
The company continues to actively engage with global pharmaceutical companies, biotech partners, and investors to accelerate development and bring this transformative technology to market. As a preclinical-stage biotechnology company, Optigo is developing a proprietary platform that anchors intravitreal biologics to endogenous proteins like albumin and hyaluronan, significantly prolonging half-life and therapeutic activity.